Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Google Secures Pentagon AI Deal for Classified Projects 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
NOVATO, Calif., Feb. 09, 2016 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company’s Chief Financial Officer, will be presenting at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 8:00am ET at the Waldorf Astoria in New York, NY.
The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Ryan Martins 844-758-7273
